MAPT and dementia: A recent report from the Genetic Frontotemporal Dementia Initiative (GENFI) used multiplexed assays to measure CSF and plasma levels of complement components and activation products in FTD cases with known genetic mutations in MAPT, C9ORF or GRN at different stages of the disease [112].